Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Change in Receivables (2022 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Change in Receivables for 4 consecutive years, with -$6.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 677.71% to -$6.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.6 million, a 107.68% increase, with the full-year FY2025 number at $7.6 million, up 107.68% from a year prior.
  • Change in Receivables was -$6.2 million for Q4 2025 at Rhythm Pharmaceuticals, down from $6.6 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $7.8 million in Q2 2025 to a low of -$6.2 million in Q4 2025.
  • A 4-year average of $1.7 million and a median of $1.2 million in 2023 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 286.42% in 2025; the steepest drop was 677.71% in 2025.
  • Rhythm Pharmaceuticals' Change in Receivables stood at $2.9 million in 2022, then crashed by 88.74% to $326000.0 in 2023, then plummeted by 343.56% to -$794000.0 in 2024, then tumbled by 677.71% to -$6.2 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Change in Receivables are -$6.2 million (Q4 2025), $6.6 million (Q3 2025), and $7.8 million (Q2 2025).